A phase l study of three different dosing schedules of the oral aurora kinase inhibitor MSC1992371A in patients with solid tumors.
about
Recent advances in the development of Aurora kinases inhibitors in hematological malignanciesInhibition of Aurora kinase B is important for biologic activity of the dual inhibitors of BCR-ABL and Aurora kinases R763/AS703569 and PHA-739358 in BCR-ABL transformed cellsThe aurora kinases in cell cycle and leukemiaMicrotubule-targeting agents in oncology and therapeutic potential in hepatocellular carcinoma.Multi-kinase inhibitors, AURKs and cancer.Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies.
P2860
A phase l study of three different dosing schedules of the oral aurora kinase inhibitor MSC1992371A in patients with solid tumors.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
A phase l study of three diffe ...... in patients with solid tumors.
@ast
A phase l study of three diffe ...... in patients with solid tumors.
@en
type
label
A phase l study of three diffe ...... in patients with solid tumors.
@ast
A phase l study of three diffe ...... in patients with solid tumors.
@en
prefLabel
A phase l study of three diffe ...... in patients with solid tumors.
@ast
A phase l study of three diffe ...... in patients with solid tumors.
@en
P2093
P2860
P1433
P1476
A phase l study of three diffe ...... in patients with solid tumors.
@en
P2093
A Gianella-Borradori
D Mendelson
J Sarantopoulos
K Sankhala
P2860
P2888
P304
P356
10.1007/S11523-013-0288-3
P577
2013-07-06T00:00:00Z
P6179
1047272018